Home » Posts tagged 'oxford stone'
Tag Archives: oxford stone
Feedback PLC announces it has licensed TexRAD to Stone Checker
Feedback plc (FDBK), the medical imaging software company, previously announced on 13 April 2015 that it had signed a research agreement with the Oxford Stone Group at the University of Oxford & Oxford University Hospital NHS Trust, UK to investigate the potential future clinical application of Feedback’s TexRAD texture analysis software on computed tomography (CT) image data of patients with kidney stones. On 11 May 2015, Feedback announced the pilot results from a preliminary feasibility study.
A larger retrospective validation study comprising 90 patients carried out by the Oxford research team led by Mr Ben Turney (Bernard Senior Clinical Researcher in Urology at the University of Oxford and Honorary Consultant Urological Surgeon) is currently under way.
Following these studies, Feedback is pleased to announce the incorporation of a 50:50 joint venture company “Stone Checker Software Ltd” with U.K. Urology Associates Limited (UKUA) to commercialise the specific application of TexRAD texture analysis in Urolithiasis. To facilitate this, Feedback Plc has granted a licence of TexRAD intellectual property to Stone Checker.
UKUA has expertise in a wide range of technology applications in the specialist Urology field. This knowledge extends from the development and distribution of novel medical equipment for both benign and malignant urological diseases through to the use of software in urodynamics. The team comprises an experienced group of healthcare technology innovators.
The vision of Stone Checker is to develop a composite risk stratification software product following stringent clinical standards and regulatory standards. TexRAD CT texture analysis will be incorporated with other known clinical markers to develop an integrated product which would potentially assist urologists and radiologists to provide better patient management and treatment decisions for improved patient outcomes. There is a large potential worldwide market for a non-invasive risk stratification tool based on the common occurrence of kidney stones around the world.
Mr Jeevan Virk, Chief Operations Officer of UKUA commented: “The opportunity to collaborate with Feedback plc in the development of a specific urological software is hugely exciting and will provide enormous benefits to patients who will receive appropriate therapy, clinicians who will be able to optimise their use of time and improve success rates, and the healthcare payers who will no longer have to pay for high failure rates in lithotripsy. It is unusual to have a product which fully lines up to provide benefits to the whole clinical team, but this is the promise of Stone Checker software.”
Dr. Balaji Ganeshan, Chief Scientist & New Business Officer of the Company’s subsidiaries TexRAD Ltd & Cambridge Computed Imaging Ltd commented: “We are delighted with the formation of a new JV company with UKUA, Stone Checker Software Ltd, to develop a novel composite clinical score based software product dedicated to the management of kidney stone patients.”
For further information contact:
|
Feedback plc |
Tel: 01954 718072 |
|
Simon Barrell / Trevor Brown / Tom Charlton |
|
|
Sanlam Securities UK (Nominated Adviser and Joint Broker) |
Tel: 020 7628 2200 |
|
Simon Clements / Virginia Bull |
|
|
Peterhouse Corporate Finance Ltd(Joint Broker) |
Tel: 020 7469 0936 |
|
Lucy Williams / Duncan Vasey |
Feedback PLC announces preliminary results from the Oxford Stone Group using TexRAD research software in the analysis of kidney stones
Feedback plc previously announced on 13 April 2015 that it had signed a research agreement with the Oxford Stone Group at the University of Oxford & Oxford University Hospital NHS Trust, UK to investigate the potential future clinical application of Feedback’s TexRAD texture analysis software on computed tomography (CT) image data of patients with kidney stones.
The preliminary results from a 38 patient retrospective study so far are promising. Researchers at Oxford have demonstrated that TexRAD texture analysis could identify from pre-treatment CT scans which patients would have “successful” shockwave lithotripsy (SWL) therapy from those who would have “unsuccessful” therapy.
The research was led by Mr Ben Turney (Bernard Senior Clinical Researcher in Urology at the University of Oxford and Honorary Consultant Urological Surgeon) and carried out by Mr Daniel Stevens (Academic Clinical fellow in Urology at the University of Oxford).
Mr Ben Turney, a leading authority on stone disease in the UK, commented: “Shock Wave Lithotripsy (SWL) is a well-established non-invasive surgical procedure for urolithiasis. However around 30-40% of patients do not achieve stone clearance and proceed to alternative treatments. We have demonstrated in this first preliminary study that TexRAD CT textural analysis appears to be an independent novel predictive biomarker for SWL success. TexRAD CT texture analysis may be a useful tool for risk-stratification and more accurately triaging those patients who will benefit from SWL. The next step is to undertake a prospective study to ascertain the clinical utility of this finding in a large population. Additionally, we shall explore other research questions such as assessing the stone composition and differentiate between actual stones and those conditions that mimic stone-like characteristics to increase diagnostic confidence and prevent unnecessary costly investigation and treatments.”
Dr. Balaji Ganeshan, Chief Scientist & New Business Officer of the Company’s subsidiaries TexRAD Ltd & Cambridge Computed Imaging Ltd commented: “We are delighted with the positive results from the preliminary study within a few weeks of signing the research agreement with Mr Ben Turney and the team at Oxford. This is very encouraging news and provides an opportunity for Feedback Plc to develop a TexRAD based kidney stone software product dedicated to the management of kidney stone patients.”
Mr Ben Turney and team have further submitted their preliminary results as an abstract for a possible presentation to the Challenges in Endourology meeting (http://www.challenges-endourology.com) in Paris in June 2015.
For further information contact:
Feedback plc
Tel: 01954 718072
Simon Barrell / Trevor Brown / Tom Charlton
Sanlam Securities UK (Nominated Adviser and Joint Broker)
Tel: 020 7628 2200
Simon Clements / Virginia Bull
Peterhouse Corporate Finance Ltd (Joint Broker)
Tel: 020 7469 0936
Lucy Williams / Duncan Vasey